Tessa A. Groeneweg

Tessa A. Groeneweg

Auto-generated profile, based on publicly available information

Tessa A. Groeneweg

Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
JCJessica Conti
Jessica Conti
DADora Angyal
Dora Angyal
KKKarina Kleinfelder
Karina Kleinfelder
RLRoberta Valeria Latorre
Roberta Valeria Latorre
MCMartina Calicchia
Martina Calicchia
Claudio SorioClaudio Sorio
Claudio Sorio
Cystic fibrosis (CF) is caused by mutation of the CFTR gene, encoding an epithelial anion channel. Here we evaluated the effect of the modulator combination elexacaftor-tezacaftor-ivacaftor (ETI) on the function of four rare, poorly characterized CFTR variants: L383S, I507del, L1065P and R1066H. Intestinal organoids were obtained from subjects carrying the CFTR variants L383S, I507del, L1065P or R1066H in trans of a minimal function allele (class I mutation). Organoids and epithelial monolayers were used to assess the effect of ETI on CFTR protein abundance and CFTR-mediated chloride, bicarbonate, and fluid transport. In L383S-CFTR expressing cells, normal levels of fully glycosylated CFTR protein (C-band) were detected. In contrast, in I507del, L1065P or R1066H organoids, only partially glycosylated CFTR (B-band) was detected. Chloride/bicarbonate transport was severely impaired in epithelial monolayers prepared from these latter three variants, while anion transport of the L383S variant was affected to a moderate extent. ETI, but not ivacaftor alone, significantly enhanced CFTR-mediated chloride and bicarbonate transport in L1065P and R1066H monolayers, and stimulated fluid transport. A corresponding increase in the abundance of C-band protein was observed in both variants. ETI also modestly improved L383S-CFTR function, with a marginal effect on I507del-CFTR. The I507del, L1065P and R1066H variants display severely impaired function. ETI treatment markedly enhanced L1065P- and R1066HCFTR function, whereas its effect on L383S- CFTR was less pronounced. Consequently, ETI may ameliorate disease symptoms in individuals carrying the L1065P or R1066H variant. More tentative, it may also benefit those carrying the L383S variant.

24 April 2023 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
JLJ.W. Lefferts
J.W. Lefferts
VBV. Boersma
V. Boersma
NNN.D.A. Nieuwenhuijze
N.D.A. Nieuwenhuijze
SSS.W.F. Suen
S.W.F. Suen
KHK. Hajo
K. Hajo
JBJeffrey M. Beekman
Jeffrey M. Beekman

7 October 2026 in Pancreatology
Verified
Journal Article
Open access
DADora Angyal
Dora Angyal
EBErdene Baigal
Erdene Baigal
TGTessa A. Groeneweg
Tessa A. Groeneweg
LMLayla Moesker
Layla Moesker
WLWillem J. Lammers
Willem J. Lammers
MBMarcel J.C. Bijvelds
Marcel J.C. Bijvelds